Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

doc reviewing lung report | Image Credit: © meeboonstudio - stock.adobe.com
November 8th 2024

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma

Karen Jacobson-Sive
Rituximab-induced interstitial lung disease in patients with non-Hodgkin lymphoma presents with distinct clinical characteristics and bronchoalveolar lavage results.
Karen Winkfield, MD, PhD
November 7th 2024

Adapting Cancer Treatment for Survivorship and Precision Care

Maggie L. Shaw
The American Journal of Managed Care® and Vanderbilt University Medical Center partnered on a recent Institute for Value-Based Medicine® event, which had the theme, “Bringing the Future to the Present in Cancer Care.”
Fish oil supplements in fish shape | Image credit: zilvergolf – stock.adobe.com
November 5th 2024

High Omega-3, Omega-6 Levels May Lower Cancer Risk

Hayden E. Klein
Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.
Cancer disparities | Image credit: Yurii Kibalnik - stock.adobe.com
November 4th 2024

Disparities in Cancer Mortality Among Asian Americans and Pacific Islanders

Pearl Steinzor
Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.
Smoking | Image credit: ehabeljean - stock.adobe.com.jpg
October 31st 2024

Early Smoking Cessation Treatment After Cancer Diagnosis Improves Survival

Pearl Steinzor
Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
October 28th 2024

Transforming Oncology Care With AI-Driven Insights

Pearl Steinzor
Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.
Vinayak Venkataraman, MD
October 24th 2024

Sarcoma Care: Biomarker Advancements Shape the Future

Maggie L. Shaw
At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Gut health concept | Image credit: faithie - stock.adobe.com
October 23rd 2024

Ixcela, Roper St. Francis Healthcare Launch Innovative Cancer Support Program to Improve Treatment Outcomes

Pearl Steinzor
A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
October 21st 2024

Bridging the Digital Divide of Rural Cancer Care With Telehealth

Cameron Santoro
Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.
Hari Deshpande, MD, Yale Cancer Center
October 17th 2024

Elevating Sarcoma Outcomes Through Value-Based Care

Maggie L. Shaw
At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.
Advancing health equity can be achieved through community engagement | image credit: Andrii - stock.adobe.com
October 16th 2024

Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity

Kyle Munz
Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Screenshot of an interview with Terry Keys
October 16th 2024

Combatting Misconceptions of Clinical Trials to Improve Patient Participation

Laura Joszt, MA
There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Screenshot of an interview with Naoto Ueno, MD, PhD
October 15th 2024

Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage

Alexandra Gerlach Laura Joszt, MA
Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Medicinal cannabis | image: NJ.gov
October 14th 2024

Navigating the Complexities of Cancer Care: Cannabis and Cost Considerations

Laura Joszt, MA
Doing Things Differently: Wilfong Moves to Thyme Care
October 12th 2024

Doing Things Differently: Wilfong Moves to Thyme Care

Mary Caffrey
Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.
Oncology models | Image credit: Navista
October 11th 2024

Tangle of Tech: How Community Oncology Practices Can Successfully Navigate the Health Technology Landscape

Nini Wu, MD, MBA Anish Arora
Patient Navigation | Image credit: CDC
October 11th 2024

Setting the Course for Comprehensive Care Navigation in Oncology

Vishnukamal Golla, MD, MPH Allan Zuckoff, PhD Lucy MacPhail, PhD John Tam, MD Chevon Rariy, MD
AJMC
October 11th 2024

Racial and Ethnic Disparities in Prior Authorizations for Patients With Cancer

Benjamin Ukert, PhD Stephanie Schauder, PhD Daniel Cullen, PhD David Debono, MD Michael Eleff, MD Michael J. Fisch, MD, MPH
The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.
Corey McEwen, PharmD, MS
October 10th 2024

Defining Value in Oncology Pharmacy: Insights on Care and Costs

Maggie L. Shaw
The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.
Hands holding green lymphoma ribbon | Image credit: sulit.photos - stock.adobe.com
October 9th 2024

Childhood Lymphoma: Raising Awareness for Early Detection and Better Outcomes

Pearl Steinzor
It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for support.
Cancer screening | Image credit: kenchiro168 - stock.adobe.com
October 3rd 2024

Fear of Recurrence Is Common Among Adult Survivors of Childhood Cancer

Pearl Steinzor
Adults who survived childhood cancer experience elevated fear that their primary cancer will recur or that a subsequent malignant neoplasm will develop, according to a new study.
Managing AEs of Cannabis Use in Patients With Cancer
September 29th 2024

Managing AEs of Cannabis Use in Patients With Cancer

Laura Joszt, MA
There are some short-lived, common adverse events for patients using cannabis, but also some more dangerous, less common ones in chronic users, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
dr linda bosserman
September 27th 2024

Expanding Access to Innovative Cancer Treatments

Brooke McCormick
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, discusses the implementation of cutting-edge cancer treatments, emphasizing the need for effective information sharing and collaboration to improve cancer care access for diverse populations.
dr andrew leitner
September 26th 2024

Increasing Access to Supportive Oncology Care Can Drive Health Equity

Brooke McCormick
Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.
Closing Gaps in Value-Based Cancer Care
September 25th 2024

Closing Gaps in Value-Based Cancer Care

Brooke McCormick
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.
Ted Okon, MBA
September 24th 2024

New FTC Lawsuit Against PBMs Has Broad Implications for Pharmaceuticals, Ted Okon Says

Julia Bonavitacola Skylar Jeremias
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit managers (PBMs) could affect the future of pharmaceuticals and oncology.
dr andrew leitner
September 24th 2024

Spotlighting the Critical Role of Supportive Care in Cancer Treatment

Brooke McCormick
Andrew Leitner, MD, City of Hope, highlights the essential role of supportive care in improving the quality of life of patients with cancer undergoing treatment.
Chemotharapy graphic-tashatuvango-stock.adobe.com.jpeg
September 23rd 2024

Higher Risk of Heart Events in Older Cancer Survivors Linked to Chemotherapy

Pearl Steinzor
New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated with chemotherapy.
Glenn Balasky during a video interview
September 22nd 2024

AI in Cancer Care Can Be Powerful, but There Will Be Learning Curves, Says Glenn Balasky

Alexandra Gerlach Laura Joszt, MA
Demonstration projects to show accurate use of artificial intelligence (AI) in cancer care are important to prevent a loss of credibility in the technology, explained Glenn Balasky, executive director, Rocky Mountain Cancer Centers.
dr joseph alvarnas
September 22nd 2024

Precision, Personalization, and Equity: Key Trends Shaping the Future of Cancer Care

Brooke McCormick
Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.
<1
...
34567891011
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo